Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications

Mechanisms of action of potential ncRNA-based immunotherapeutics. Several ncRNA-centered immunotherapies have been developed. The TGF-β1/SMAD3 signaling pathway can inhibit the expression of T-bet and IFN-γ, thereby blunting NK cell activity. CD56-NP-miR-186 improves NK cytotoxicity by targeting TGFBR1 and TGFBR2. siPD-L1@PLGA suppresses IFN-γ-mediated PD-L1 induction and induces local expansion of CD8+ T cells. pCD28-siRNA-PD-1 can increase CD28 expression and reduce PD-1 expression. It also induces antitumor immune responses by increasing the populations of CD4+ T cells and CD8+ T cells while repressing Treg expansion. EVs/siCD38 impedes CD38-mediated adenosine generation and facilitates macrophage repolarization toward tumor-suppressive M1-like phenotype. CD.siRNA.stearic acid-PEG-SA induces the reprograming of M2 macrophages to M1 phenotype by silencing CSF-1R. These ncRNA-based approaches can reverse cancer resistance to conventional immunotherapies and hold great promise for the clinical use in cancer treatment. IFN-γ, interferon-γ; TGFBR1, transforming growth factor-β receptor 1; TGFBR2, transforming growth factor-β receptor 2; NK cell, natural killer cell; Treg, regulatory T cell; TGF-β1, transforming growth factor-β1; IFNγR, interferon-γ receptor; PD-L1, programmed cell death-ligand 1; PD-1, programmed cell death protein-1; MDSC, myeloid-derived suppressive cell; TAM, tumor-associated macrophage; CSF-1R, colony stimulating factor-1 receptor.
Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications

Publication

Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications. (2023) Man Wang, et al. Front Immunol. 2023;14:1268745. Figure: F7.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates CD4+ CD4 ncbigene_symbol CD4 920
Homo sapiens Primates CD8+ CD8 ncbigene_synonym CD8A 925
Homo sapiens Primates CD8+ CD8 famplex_relations CD8B 926
Homo sapiens Primates TAM TAM ncbigene_symbol TAM 8205
Homo sapiens Primates TAM TAM ncbigene_synonym STIM1 6786
Homo sapiens Primates T-bet T-BET ncbigene_synonym TBX21 30009
Homo sapiens Primates TGFBR1- TGFBR1 ncbigene_symbol TGFBR1 7046
Homo sapiens Primates CD56 CD56 ncbigene_synonym NCAM1 4684
Homo sapiens Primates TGFBR2 TGFBR2 ncbigene_symbol TGFBR2 7048
Homo sapiens Primates CD28 CD28 ncbigene_symbol CD28 940
Homo sapiens Primates TGF-B1 TGF-B1 ncbigene_synonym TGFB1 7040
Homo sapiens Primates CD38 CD38 ncbigene_symbol CD38 952
Homo sapiens Primates IFNYR IFNGR ncbigene_synonym IFNGR1 3459
Homo sapiens Primates PD-L1 PD-L1 ncbigene_synonym CD274 29126
Homo sapiens Primates CSF-1R! CSF1R ncbigene_symbol CSF1R 1436
Homo sapiens Primates PD-1 PD-1 ncbigene_synonym PDCD1 5133
Homo sapiens Primates PD-1 PD-1 ncbigene_synonym RPL17 6139
Homo sapiens Primates PD-1 PD-1 ncbigene_synonym RPL17-C18orf32 100526842
Homo sapiens Primates CD169 CD169 ncbigene_synonym SIGLEC1 6614

Chemical mentions

Word Match MeSH Name ChEBI
PLGA NA mesh:C043435
stearic acid NA mesh:D013229
PEG NA mesh:C499599
TAM NA mesh:C419191
Adenosine Adenosine mesh:D000241 adenosine chebi:16335

Disease mentions

Word Match MeSH Name DOID
Cancer NA mesh:D009369